Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial
A Pardanani, C Harrison, JE Cortes, F Cervantes… - JAMA …, 2015 - jamanetwork.com
Importance Myelofibrosis (MF) is aBCR-ABL–negative myeloproliferative neoplasm
characterized by anemia, splenomegaly, debilitating constitutional symptoms, and
shortened survival. Fedratinib, a JAK2-selective inhibitor, previously demonstrated clinically
beneficial activity in patients with MF in early-phase trials. Objective To evaluate the efficacy
and safety of fedratinib therapy in patients with primary or secondary (post–polycythemia
vera or post–essential thrombocythemia) MF. Design, Setting, and Participants Double …
characterized by anemia, splenomegaly, debilitating constitutional symptoms, and
shortened survival. Fedratinib, a JAK2-selective inhibitor, previously demonstrated clinically
beneficial activity in patients with MF in early-phase trials. Objective To evaluate the efficacy
and safety of fedratinib therapy in patients with primary or secondary (post–polycythemia
vera or post–essential thrombocythemia) MF. Design, Setting, and Participants Double …
以上显示的是最相近的搜索结果。 查看全部搜索结果